Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer.

Yagita, Mayu; Ieki, Y; Onishi, Rei; Huang, Cheng‐Long; Adachi, Masashi; Horiike, Shigeo; Konaka, Yoshiteru; Taki, Toshihiko; Miyake, Masayuki

doi:10.3892/ijo.13.1.91

Cited by 18 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral etoposide has significant activity in platinum‐refractory ovarian cancer, with documented response rates from 6% to 32% 104‐106. However, it is not commonly used, possibly because of secondary hematologic malignancies associated with its use 107. In GOG trials, 3 of 150 patients treated with oral etoposide (2%) developed secondary myelodysplastic syndrome or acute myelogenous leukemia within 18 months of therapy.…”

Section: Treatmentmentioning

confidence: 99%

Recent progress in the diagnosis and treatment of ovarian cancer

Jelovac

Armstrong

2011

CA: A Cancer Journal for Clinicians

681

568

View full text Add to dashboard Cite

Epithelial ovarian cancer is the most lethal of the gynecologic malignancies, largely due to the advanced stage at diagnosis in most patients. Screening strategies using ultrasound and the cancer antigen (CA) 125 tumor marker are currently under study and may lower stage at diagnosis but have not yet been shown to improve survival. Women who have inherited a deleterious mutation in the BRCA1 or BRCA2 gene and those with the Lynch syndrome (hereditary nonpolyposis colorectal cancer) have the highest risk of developing ovarian cancer but account for only approximately 10% of those with the disease. Other less common and less well-defined genetic syndromes may increase the risk of ovarian cancer, but their contribution to genetic risk is small. A clear etiology for sporadic ovarian cancer has not been identified, but risk is affected by reproductive and hormonal factors. Surgery has a unique role in ovarian cancer, as it is used not only for diagnosis and staging but also therapeutically, even in patients with widely disseminated, advanced disease. Ovarian cancer is highly sensitive to chemotherapy drugs, particularly the platinum agents, and most patients will attain a remission with initial treatment. Recent advances in the delivery of chemotherapy using the intraperitoneal route have further improved survival after initial therapy. Although the majority of ovarian cancer patients will respond to initial chemotherapy, most will ultimately develop disease recurrence. Chemotherapy for recurrent disease includes platinum-based, multiagent regimens for women whose disease recurs more than 6 to 12 months after the completion of initial therapy and sequential single agents for those whose disease recurs earlier. New targeted biologic agents, particularly those involved with the vascular endothelial growth factor pathway and those targeting the poly (ADP-ribose) polymerase (PARP) enzyme, hold great promise for improving the outcome of ovarian cancer.

show abstract

Section: Treatmentmentioning

confidence: 99%

Recent progress in the diagnosis and treatment of ovarian cancer

Jelovac

Armstrong

2011

CA: A Cancer Journal for Clinicians

681

568

View full text Add to dashboard Cite

show abstract

“…50–100 mg/m 2 /day) is associated with a decreased risk of this complication is uncertain. To date, only a few patients treated on this schedule have developed AML ( Stine et al , 1997 ; Yagita et al , 1998 ), although these studies have been limited to patients with relapsed or refractory cancers and short follow‐up times. In this regard, our in vitro study demonstrated that prolonged exposures to low concentrations of this agent (a schedule mimicking oral dosing) were associated with a lower frequency of non‐homologous site‐specific DNA recombination, an event predisposing to AML induction, than were brief exposures to high concentrations of etoposide (a schedule commonly used for patients with leukaemia) ( Chen et al , 1996b ).…”

Section: Risk Factorsmentioning

confidence: 99%

Topoisomerase Ii Inhibitor‐related Acute Myeloid Leukaemia

2000

View full text Add to dashboard Cite

“…Of these, 11 were excluded from analysis for the following reasons: insufficient details available in two, 17,18 no anti-leukemic treatment administered in three (including current case 2), 19,20 prior radiation therapy only in three, 13,21,22 aberrant breakpoints in one 23 unacknowledged multiple publication in one, 19,24 and finally, one case included in an earlier review (patient number 5 from Quesnel et al 12 ) could not be verified from the primary reference cited. 25 Thus, 25 cases with treatment and follow-up data were available for analysis 6,[12][13][14]19,[26][27][28][29] (Table 1).…”

Section: Previously Reported Cases Of S-aml With Inv(16)mentioning

confidence: 99%

Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy

et al. 1999

View full text Add to dashboard Cite

Acute myeloid leukemia developing secondary to prior cytotoxic chemotherapy (s-AML) encompasses a range of distinct entities. We report two cases of s-AML with inv(16)(p13q22) who had prior exposure to paclitaxel. Additionally, two previously reported cases of s-AML with inv(16) had prior paclitaxel exposure raising the possibility that the taxanes may predispose to this specific syndrome of s-AML. One of our patients received escalated-dose ara-C chemotherapy, achieving a complete remission (12+ months). We therefore examined the prognosis of previously reported cases of s-AML with inv(16) and analyzed the influence of escalated-dose ara-C (у400 mg/m 2 /day). A total of 25 evaluable cases were identified, with 96% attaining CR independent of ara-C dose. The estimated median remission duration was 40 months and the median survival has not been reached (actuarial 5-year survival 52 ± 18%). Although not achieving statistical significance, patients treated with escalated dose ara-C (n = 15) had longer remission duration and overall survival than those treated with standard dose ara-C (n = 10) (P = 0.063 and 0.20, respectively). In univariate analysis, younger age, male gender, and the presence of additional cytogenetic abnormalities were associated with a tendency towards adverse outcomes (P Ͻ 0.1). Age and gender were equally distributed between ara-C dose cohorts, but more patients treated with standard-dose ara-C had additional cytogenetic abnormalities (P = 0.048). Within the limitations of this retrospective study, this analysis suggests that, similar to de novo AML with inv(16), secondary cases may also potentially benefit from treatment with escalated-dose ara-C. This is consistent with the premise that the underlying molecular defect, rather than the presence of prior cytotoxic drug exposure, may be the most important determinant of disease behavior and chemotherapy responsiveness in AML.

show abstract

Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer.

Cited by 18 publications

References 0 publications

Recent progress in the diagnosis and treatment of ovarian cancer

Recent progress in the diagnosis and treatment of ovarian cancer

Topoisomerase Ii Inhibitor‐related Acute Myeloid Leukaemia

Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy

Contact Info

Product

Resources

About